Virtual Care for Diabetes: Commercialization models

In the past few years, the prevalence of type 2 diabetes (T2-diabetes) has increased dramatically, currently being 90-95% of all diagnosed cases of diabetes in US adults. As T2-diabetes is considerably attributed to reversible behaviours, there is a big opportunity to remotely prevent and manage the onset of this disease and also enable regular, ongoing monitoring post diagnosis and treatment. Actually, T2-diabetes is one of the cardiometabolic diseases where digital health has the highest penetration and has shown more clinical and economic evidence so far. But beyond having the evidence, choosing the right commercialization model is a key to success for virtual care companies operating in the space. Join us in this informal conversation where we will discuss: